Stockreport

European Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib, Advancing Treatment Paradigm in Europe

TAKEDA PHARMA  (TKPYY) 
NASDAQ:AMEX Investor Relations: takeda.com/investors
PDF – ALUNBRIG Demonstrated Unprecedented Median Progression-Free Survival of 16.7 Months and Overall Survival of 34.1 Months in the Post-Crizotinib Setting [Read more]